Welcome to our dedicated page for NOVO news (Ticker: NOVO), a resource for investors and traders seeking the latest updates and insights on NOVO stock.
The news items provided for Novo Nordisk A/S (NOVO) focus on its role as a bidder in a potential acquisition of Metsera, Inc. The excerpts describe both an unsolicited proposal and an amended proposal from Novo Nordisk A/S that Metsera’s Board of Directors determined to be a "Superior Company Proposal" under Metsera’s existing merger agreement with Pfizer.
According to these announcements, Novo Nordisk A/S structured its proposals in two steps. The first step involves a cash payment per Metsera common share and the issuance of non-voting preferred stock representing a portion of Metsera’s share capital to Novo Nordisk A/S, along with a declared cash dividend to Metsera shareholders. The second step, contingent on shareholder and regulatory approvals, would provide Metsera shareholders with a contingent value right tied to development and regulatory approval milestones and would result in Novo Nordisk A/S acquiring the remaining outstanding shares.
News related to NOVO in this context centers on comparative transaction valuations, the premium to Metsera’s prior trading price, and the interaction between the Novo Nordisk A/S proposals and the existing Pfizer merger agreement. The announcements also discuss the contractual negotiation periods triggered when Metsera notifies Pfizer that a competing proposal from Novo Nordisk A/S has been deemed superior.
Readers following NOVO-related news in this dataset can review how the terms of the initial and amended proposals evolved, how Metsera’s Board evaluated those terms, and how they compared to a revised proposal from Pfizer. This provides insight into the transaction mechanics, valuation ranges, and governance processes that shape competitive acquisition situations involving Novo Nordisk A/S and other counterparties.
Metsera (NASDAQ: B) announced its board has declared an amended acquisition proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal values Metsera at up to $86.20 per share (~$10.0B), including an immediate cash payment/dividend of $62.20 per share and a second-step contingent value right (CVR) of up to $24.00 per share. Metsera notified Pfizer, triggering a two-business-day negotiation period under the Pfizer Merger Agreement.
Metsera (NASDAQ: B) announced that its board has declared an amended proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer on Nov 4, 2025. The Novo Nordisk Amended Proposal values Metsera at up to $86.20 per share (~$10.0 billion) via a two-step structure: an immediate $62.20 per share cash payment plus non-voting preferred stock, followed by a dividend of $62.20, and a contingent value right (CVR) worth up to $24.00 per share upon regulatory and development milestones.
Metsera notified Pfizer, triggering a two-business-day period for Pfizer to propose adjustments under the Pfizer Merger Agreement; Pfizer previously revised its proposal to $60.00 upfront + up to $10.00 CVR.
Metsera (NASDAQ: B) announced its board has declared an unsolicited proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal would pay $56.50 per share in cash at signing, issue Novo non-voting preferred stock representing 50% of Metsera's share capital, then pay a CVR up to $21.25 per share upon milestones, valuing Metsera at up to $77.75 per share (~$9 billion).
The proposal represents an approximate 133% premium to Metsera's close on Sept 19, 2025. Metsera notified Pfizer, triggering a four-business-day period for Pfizer to propose adjustments; Pfizer disputes Metsera's right to deliver the notice. The Pfizer merger agreement remains in effect and Metsera's board reaffirmed its recommendation to approve the Pfizer transaction; no shareholder action is required now.